

Introduction to CRISPR-Cas9 KO screening


Dr Saroor Patel
Senior Staff Scientist, Garnett Lab

10th Oct 2024

Introduction to CRISPR-Cas9 KO screening


1. The CRISPR-Cas9 system
2. Overview of pooled CRISPR-Cas9 KO screens
3. CRISPR-Cas9 sgRNA libraries
4. Lentiviral Transduction
5. Functional assays
6. Overview of arrayed screening
7. Pooled vs arrayed screening
8. Applications
9. Parallel approaches

The CRISPR-Cas9 system




Adapted from Ran et al. Nature Protocols 2013

The CRISPR-Cas9 system




Adapted from Ran et al. Nature Protocols 2013

Overview of pooled CRISPR-Cas9 KO screens




CRISPR-Cas9 KO sgRNA libraries




- Guide design: many web-based tools for picking effective sgRNAs (e.g. CRISPick from Broad Institute, Vienna Bioactivity Score)
- At least 2 guides per gene to increase confidence in data and mitigate potential off-target effects (4 is recommended)
- Positive and negative control guides need to be included within each library
- Guide cloning: guide distribution should be as homogeneous as possible to improve data quality
- For Human genome-wide libraries, various plasmid libraries available on Addgene
- Multiplexing (more than 1 sgRNA per vector, e.g. dual perturbation)

Lentiviral Transduction

3 Lentivirus packaging and infection of Cas9-expressing cells at low MOI



4 Selection and genome editing in Cas9-expressing cells



- **Low MOI** (0.3-0.5) = 25-40% positive cells pre-selection= 86-77% single infected cells
- Cell model chosen for screening needs to be able to grow at scale and be transduced
- Cas9-expressing cells: high Cas9 efficiency is essential, measure Cas9 activity prior to screening (>75%)
- Cas9 expression single cell clones with high Cas9 activity can be isolated from cell line of interest to ensure more homogeneous population
- Cas9 expression or sgRNA expression can be DOX-inducible
- Selection via antibiotic resistance marker or FACS for fluorescent marker
- Coverage: ~100-1000X per vector, is dependent on sgRNA distribution within the library (libraries with even distribution require less coverage) and on positive vs negative selection

Functional Assays

1) Viability assays (conventional)

- Edited cells are left to proliferate for 14-28 days
- sgRNA abundances are compared between the start (from cells at day 0-4 or plasmid) and end of the screen
- Cells with sgRNAs that **promote cell survival and/or proliferation** will be **enriched in the population (positive selection)**- robust, requires lower coverage
- Cells with sgRNAs that **negatively** impact cell proliferation will be depleted from the population (**negative selection**)- **these sgRNAs target genes essential for cell survival and/or proliferation**- more challenging, requires higher coverage

e.g. *Cancer Dependency Map*


Behan et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 2019

2) FACS based assays

- Edited cell populations can be sorted for desired phenotype (e.g. levels of endogenous proteins or engineered reporters) and sgRNA abundances compared in sorted populations

e.g. *Finding regulators of endogenously tagged gene expression*

Zaini et al. Endogenous HIF2A reporter systems for high-throughput functional screening. Scientific Reports 2018




3) Perturb-seq assays

- Single-cell transcriptomic read-out for each edited cell
- Shorter assays (typically less than 7 days)

e.g. *Genome-wide perturb-seq*


Replogle et al. Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell 2022

Arrayed Screening




Adapted from Shi et al. Nature Reviews Immunology 2022

Pooled vs Arrayed Screening




Bock et al. Nature Reviews Methods Primers 2022

Applications of CRISPR-Cas9 KO Screening



Parallel approaches to CRISPR-Cas9 KO screening


a Cas9 nuclease



Cas9

- Blunt DNA cut
- NGG PAM
- Guide length 20nt + scaffold
- Multiplexing possible with multiple promoters or tRNA
- Gene knock-out


b Cas12a nuclease



Cas12a

- Staggered DNA cut with 5' overhang
- TTTV PAM
- Guide length 20-24nt + short constant section 20nt
- Multiplexing from a single RNA
- Gene knock-out


Transcription repression



CRISPRi

- Deactivated form of Cas9
- No DSB
- No permanent edits
- Reversible
- Represses gene expression
- Inhibition instead of knock-out

Cas13




Cas13d

- Smaller than Cas9
- No PAM required
- RNase activity of ssRNA
- 22nt guide + short conserved scaffold
- No permanent edits in genome
- Represses gene expression
- Knock-down instead of knock-out

Adapted from Pickar-Oliver et al. Nature Reviews Molecular Cell Biology 2019

Alternate CRISPR Perturbation Technologies



Introduction to CRISPR-Cas9 KO screening

Any questions?

Contact: sp32@sanger.ac.uk